NCT07757711Not yet recruiting
Implementation of New Models of Ovarian Carcinoma Resistant to Therapy
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
The project focuses on developing new experimental models of ovarian cancer that accurately reflect patients who do not respond to first-line platinum-based treatments and who are resistant to PARP inhibitors (PARPi). These models are essential for testing new drugs or drug combinations in preclinical settings that closely mimic real clinical conditions. These models will also help to identify predictive biomarkers of treatment response and to better understand the biological mechanisms behind therapy resistance.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 26 Mar 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Aug 2036
- Lead sponsor
- Mario Negri Institute for Pharmacological Research
- Diseases
- Ovarian cancer
- NCT number
- NCT07757711
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Aug 2026 to the primary completion date, 31 Aug 2036
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- -Failure to sign the informed consent form.
Who the study is looking for
- Female patients with malignant ovarian gynecological disease.
- Age 18 years or older.
- Patients capable of providing informed consent.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.